(Q35179957)

7 August 2017

title

Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial (English)

1 reference

7 August 2017

main subject

diabetic polyneuropathy

1 reference

Andrew J M Boulton

1 reference

7 August 2017

Dan Ziegler

1 reference

7 August 2017

Phillip A Low

1 reference

7 August 2017

William J Litchy

1 reference

7 August 2017

Aaron I Vinik

1 reference

7 August 2017

Roy Freeman

1 reference

7 August 2017

Rustem Samigullin

1 reference

7 August 2017

Hans Tritschler

1 reference

7 August 2017

Ullrich Munzel

1 reference

7 August 2017

Joachim Maus

1 reference

7 August 2017

Klemens Schütte

1 reference

7 August 2017

Peter J Dyck

1 reference

7 August 2017

language of work or name

English

0 references

publication date

20 July 2011

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

2054-2060

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

7 August 2017

start time

1 September 2021

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Ranirestat for the management of diabetic sensorimotor polyneuropathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Glucose control and vascular complications in veterans with type 2 diabetes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Postmarketing surveillance of adverse drug reactions: a correlational study approach using multiple data sources

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Detection, characterization, and staging of polyneuropathy: assessed in diabetics

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

The Rochester Diabetic Neuropathy Study: Reassessment of tests and criteria for diagnosis and staged severity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Effects of alpha-lipoic Acid on body weight in obese subjects

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Effect of a multifactorial intervention on mortality in type 2 diabetes

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Diabetic neuropathies: a statement by the American Diabetes Association

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161301

Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials

27 September 2018

1 reference

12 December 2020

Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity

1 reference

12 December 2020

Whither clinical research in diabetic sensorimotor peripheral neuropathy? Problems of end point selection for clinical trials

1 reference

12 December 2020

Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society

1 reference

12 December 2020

Identifiers

DOI

10.2337/DC11-0503

1 reference

7 August 2017

1 reference

7 August 2017

1 reference